MY179756A - Stabilized efinaconazole formulations - Google Patents

Stabilized efinaconazole formulations

Info

Publication number
MY179756A
MY179756A MYPI2016000570A MYPI2016000570A MY179756A MY 179756 A MY179756 A MY 179756A MY PI2016000570 A MYPI2016000570 A MY PI2016000570A MY PI2016000570 A MYPI2016000570 A MY PI2016000570A MY 179756 A MY179756 A MY 179756A
Authority
MY
Malaysia
Prior art keywords
stabilized
formulations
efinaconazole formulations
stabilized efinaconazole
acid
Prior art date
Application number
MYPI2016000570A
Other languages
English (en)
Inventor
Varsha Bhatt
Nayan Desai
Radhakrishnan Pillai
Original Assignee
Dow Pharmaceutical Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52777446&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY179756(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dow Pharmaceutical Sciences filed Critical Dow Pharmaceutical Sciences
Publication of MY179756A publication Critical patent/MY179756A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Cosmetics (AREA)
MYPI2016000570A 2013-10-03 2014-10-02 Stabilized efinaconazole formulations MY179756A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361886569P 2013-10-03 2013-10-03
US201461922867P 2014-01-01 2014-01-01
PCT/US2014/058911 WO2015051183A1 (en) 2013-10-03 2014-10-02 Stabilized efinaconazole compositions

Publications (1)

Publication Number Publication Date
MY179756A true MY179756A (en) 2020-11-12

Family

ID=52777446

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2016000570A MY179756A (en) 2013-10-03 2014-10-02 Stabilized efinaconazole formulations

Country Status (13)

Country Link
US (4) US9662394B2 (enExample)
EP (1) EP3052487B1 (enExample)
JP (3) JP6516759B2 (enExample)
KR (1) KR102320051B1 (enExample)
CN (2) CN110433291B (enExample)
AU (1) AU2014329421B2 (enExample)
CA (1) CA2924748C (enExample)
IL (1) IL244850B (enExample)
MX (1) MX363386B (enExample)
MY (1) MY179756A (enExample)
PH (1) PH12016500586B1 (enExample)
SG (1) SG11201602596UA (enExample)
WO (1) WO2015051183A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175810A1 (en) 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
US8039494B1 (en) 2010-07-08 2011-10-18 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
WO2015051183A1 (en) 2013-10-03 2015-04-09 Dow Pharmaceutical Sciences, Inc. Stabilized efinaconazole compositions
CN112999223A (zh) * 2013-11-22 2021-06-22 博世健康爱尔兰有限公司 抗感染的方法、组合物和装置
CN106918672B (zh) * 2015-12-28 2021-02-09 中美华世通生物医药科技(武汉)有限公司 利用hplc测定艾氟康唑原料药及其制剂中有关物质的方法
EP3556368B1 (en) * 2016-12-16 2021-05-26 Kaneka Corporation Onychomycosis therapeutic agent
WO2019077163A2 (en) * 2017-10-20 2019-04-25 Galenicum Health S.L. PHARMACEUTICAL DEVICE
JP7430070B2 (ja) * 2019-02-08 2024-02-09 沢井製薬株式会社 エフィナコナゾール含有爪外用液
KR102060546B1 (ko) 2019-06-07 2019-12-30 주식회사 바이오빌리프 에피나코나졸을 함유하는 용액 형태의 국소 투여용 약학 조성물
KR102352960B1 (ko) * 2019-06-07 2022-01-19 주식회사 바이오빌리프 에피나코나졸을 함유하는 용액 형태의 국소 투여용 약학 조성물
WO2021054533A2 (ko) * 2019-09-17 2021-03-25 주식회사 바이오빌리프 산으로서 소르빈산을 포함하는 안정화된 에피나코나졸-함유 약학 조성물
KR20210032665A (ko) * 2019-09-17 2021-03-25 주식회사 바이오빌리프 킬레이트화제 및 항산화제의 조합을 포함하는 안정화된 에피나코나졸-함유 약학 조성물
WO2021054531A2 (ko) * 2019-09-17 2021-03-25 주식회사 바이오빌리프 항산화제를 포함하는 안정화된 에피나코나졸-함유 약학 조성물
KR20210032672A (ko) * 2019-09-17 2021-03-25 주식회사 바이오빌리프 에피나코나졸을 함유하는 안정화된 약학 조성물
KR20210032662A (ko) * 2019-09-17 2021-03-25 주식회사 바이오빌리프 킬레이트화제를 포함하는 안정화된 에피나코나졸-함유 약학 조성물
WO2021054535A2 (ko) * 2019-09-17 2021-03-25 주식회사 바이오빌리프 킬레이트화제, 항산화제, 및 산의 조합을 포함하는 안정화된 에피나코나졸-함유 약학 조성물
KR102266145B1 (ko) 2019-09-26 2021-06-17 대봉엘에스 주식회사 비정질 에피나코나졸 고체 분산체
JP2021054781A (ja) 2019-09-26 2021-04-08 デボン エルエス,リミテッド 共結晶形エフィナコナゾール、及びその製造方法
WO2021132348A1 (ja) * 2019-12-24 2021-07-01 科研製薬株式会社 エフィナコナゾールを含有する医薬
KR102394599B1 (ko) * 2020-03-19 2022-05-06 동아에스티 주식회사 에피나코나졸을 함유하는 국소 투여용 약학 조성물
WO2021245204A1 (en) 2020-06-03 2021-12-09 The Materia Company Limited Stable formulation of efinaconazole
JP7664026B2 (ja) * 2020-08-06 2025-04-17 沢井製薬株式会社 エフィナコナゾール含有爪外用液
JP2022547755A (ja) * 2020-08-14 2022-11-16 ビーエルアンドエイチ カンパニー,リミテッド 白癬を防止又は処置するための医薬組成物
KR102729906B1 (ko) 2020-10-30 2024-11-14 주식회사 대웅제약 항진균제를 포함하는 안정화된 조성물
KR102301743B1 (ko) 2020-12-29 2021-09-13 대봉엘에스 주식회사 에피나코나졸 경구용 조성물
WO2022170147A1 (en) * 2021-02-05 2022-08-11 Acp Laboratories Llc Topical composition for treating fungi forming on a user's body
KR102863832B1 (ko) 2021-05-04 2025-09-25 주식회사 제뉴원사이언스 에피나코나졸을 함유하는 액상 형태의 약학적 조성물
WO2022235048A1 (ko) * 2021-05-04 2022-11-10 주식회사 제뉴원사이언스 에피나코나졸을 함유하는 액상 형태의 약학적 조성물
KR20230158920A (ko) 2022-05-12 2023-11-21 주식회사한국파마 에피나코나졸을 함유하는 안정화된 국소투여용 약학 조성물
KR102842759B1 (ko) 2022-05-20 2025-08-06 주식회사한국파마 항진균제로서 에피나코나졸을 함유하는 약학 조성물
KR102597564B1 (ko) * 2023-03-03 2023-11-03 장병모 조갑 및 피부 백선의 예방 또는 치료용 약학적 조성물

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE41306C (de) A. STORIE VAN DEN ABEELE in Brügge, Belgien Tabak-Trockner
US3655290A (en) 1970-10-02 1972-04-11 Griffith & Associates Inc Applicator instrument
US4052513A (en) 1974-12-13 1977-10-04 Plough, Inc. Stable topical anesthetic compositions
DE3106635A1 (de) 1981-02-23 1982-09-09 Bayer Ag Antimykotisches mittel mit hoher wirkstoff-freisetzung in form von stiften
US4384589A (en) 1981-07-27 1983-05-24 American Cyanamid Company Novel liquid delivery system for toiletries
US4912124A (en) 1984-02-23 1990-03-27 Ortho Pharmaceutical Corporation Antifungal dermatological solution
JPS6234955A (ja) 1985-08-01 1987-02-14 ダウ コ−ニング コ−ポレ−ション 透明シリコ−ン組成物
WO1987002580A1 (en) 1985-11-04 1987-05-07 Dermatological Products Of Texas Film-forming, pharmaceutical vehicles for application of medicaments to nails, pharmaceutical compositions based on those vehicles, and methods of using same
DE3544983A1 (de) 1985-12-19 1987-06-25 Hoechst Ag Antimykotisch wirksamer nagellack
US5208257A (en) * 1986-04-21 1993-05-04 Kabara Jon J Topical antimicrobial pharmaceutical compositions and methods
JPS63188609A (ja) 1987-01-30 1988-08-04 Sansho Seiyaku Kk 着色を防止した外用剤
DE3720147A1 (de) 1987-06-16 1988-12-29 Hoechst Ag Antimykotisch wirksamer nagellack sowie verfahren zu dessen herstellung
CA2008775C (en) 1989-02-24 1998-12-22 Alberto Ferro Nail lacquer
FR2673537B1 (fr) 1991-03-08 1993-06-11 Oreal Utilisation d'agents de penetration hydrophiles dans les compositions dermatologiques pour le traitement des onychomycoses, et compositions correspondantes.
US5449715A (en) * 1991-09-17 1995-09-12 Isp Investments Inc. Colorless, non-toxic, stabilized aqueous solution of a C1-C5 alkyl vinyl ether and maleic acid copolymers
CA2129828A1 (en) 1992-02-12 1993-08-19 Giovanni Lucchetti Liposomal itraconazole formulations
DE4212105A1 (de) 1992-04-10 1993-10-14 Roehm Pharma Gmbh Nagellack zur Behandlung von Onychomykosen
GB9308103D0 (en) 1993-04-20 1993-06-02 Unilever Plc Cosmetic composition
CA2162463C (en) 1993-05-10 2006-01-03 Takanobu Naito Azolylamine derivative
US5916545A (en) 1993-07-28 1999-06-29 Pfizer Inc. Antifungal nail solution
US5391367A (en) 1993-07-28 1995-02-21 Pfizer Inc. Antifungal nail solution
US5461068A (en) 1993-09-29 1995-10-24 Corwood Laboratories, Inc. Imidazole derivative tincture and method of manufacture
JP3792252B2 (ja) 1993-09-29 2006-07-05 アルザ・コーポレーション オキシブチニンのためのモノグリセリド/乳酸エステル透過促進剤
JP3608209B2 (ja) 1993-10-27 2005-01-05 大正製薬株式会社 クロタミトン配合外用剤
FR2711898B1 (fr) 1993-11-05 1995-12-29 Oreal Pinceau pour appliquer du vernis à ongles, ou un produit analogue.
US6040266A (en) 1994-02-22 2000-03-21 Ultramet Foam catalyst support for exhaust purification
FR2717057B1 (fr) 1994-03-14 1996-04-12 Oreal Pinceau de vernis à ongles et ensemble d'application de vernis à ongles muni d'un tel pinceau.
US5487776A (en) 1994-03-17 1996-01-30 Nimni; Marcel Anti-fungal nail lacquer and method therefor
US6538039B2 (en) 1994-04-29 2003-03-25 Laboratoire L. Lafon Pharmaceutical dosage form for transdermal administration
AU3633295A (en) 1994-09-07 1996-03-27 Johnson & Johnson Consumer Products, Inc. Retinoid compositions
US5696164A (en) 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
WO1996030011A1 (en) 1995-03-30 1996-10-03 Bioplex, L.C. Topical antimycotic compositions
US5549930A (en) 1995-05-25 1996-08-27 Reysis; Moisei Dryer and top coat for nail polish
US7094422B2 (en) 1996-02-19 2006-08-22 Acrux Dds Pty Ltd. Topical delivery of antifungal agents
US5696105A (en) 1996-03-14 1997-12-09 Hackler; Walter A. Antifungal nail composition
US5874069A (en) 1997-01-24 1999-02-23 Colgate-Palmolive Company Cosmetic composition containing silicon-modified amides as thickening agents and method of forming same
JP4227677B2 (ja) 1996-12-10 2009-02-18 杏林製薬株式会社 被膜形成性抗真菌剤組成物
IL132096A0 (en) 1997-03-31 2001-03-19 Johnson & Johnson Consumer Solvent system for enhanced penetration of pharmaceutical compounds
US6207142B1 (en) 1997-04-14 2001-03-27 Janssen Pharmaceutica N.V. Compositions containing an antifungal and a cationic agent
US6165484A (en) * 1997-08-26 2000-12-26 Wake Forest University EDTA and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections
US6197305B1 (en) 1998-01-05 2001-03-06 Farmo-Nat Ltd. Anti-fungal compositions with prolonged activity
KR100269323B1 (ko) 1998-01-16 2000-10-16 윤종용 반도체장치의백금막식각방법
US20020022660A1 (en) 1998-01-20 2002-02-21 Hanuman B. Jampani Deep penetrating antimicrobial compositions
US5997893A (en) 1998-01-20 1999-12-07 Ethicon, Inc. Alcohol based anti-microbial compositions with cosmetic appearance
US6022551A (en) 1998-01-20 2000-02-08 Ethicon, Inc. Antimicrobial composition
US5972358A (en) 1998-01-20 1999-10-26 Ethicon, Inc. Low tack lotion, gels and creams
US6231875B1 (en) 1998-03-31 2001-05-15 Johnson & Johnson Consumer Companies, Inc. Acidified composition for topical treatment of nail and skin conditions
BR9909351A (pt) 1998-04-03 2000-12-12 Colgate Palmolive Co Composição cosmética
US6306375B1 (en) 1998-05-01 2001-10-23 The Procter & Gamble Company Long wear nail polish having defined surface properties
US20030007939A1 (en) 1998-07-31 2003-01-09 Howard Murad Pharmaceutical compositions and methods for managing dermatological conditions
US6264927B1 (en) 1998-08-27 2001-07-24 Elmer P. Monahan Topical solution and method for the treatment of nail fungus
DE59911740D1 (de) 1998-09-10 2005-04-14 Bioequal Ag Muttenz Topisch anwendbare mittel gegen nagelpilzerkrankungen
US7026308B1 (en) 1999-06-25 2006-04-11 The Procter & Gamble Company Topical anti-microbial compositions
DE60042453D1 (de) 1999-07-28 2009-08-06 Kaken Pharma Co Ltd Verfahren zum nachweis pathogener mikroorganismen und antimikrobieller mittel, verfahren zum nachweis der arzneimittelwirkung antimikrobieller mittel und antimikrobielle mittel
MXPA02001144A (es) 1999-07-30 2002-08-20 Procter & Gamble Metodo para tratar y evitar trastornos de dedo.
JP4780429B2 (ja) * 2000-04-07 2011-09-28 大正製薬株式会社 ミノキシジル含有製剤
US6433073B1 (en) 2000-07-27 2002-08-13 3M Innovative Properties Company Polyurethane dispersion in alcohol-water system
US6676953B2 (en) 2001-01-26 2004-01-13 Don L. Hexamer Antifungal composition and method for human nails
US6585963B1 (en) 2001-02-15 2003-07-01 Watson Pharmaceuticals, Inc. Nail compositions and methods of administering same
US20030039621A1 (en) 2001-04-10 2003-02-27 L'oreal Two-coat make-up product, its use and a kit containing the make-up product
US6664292B2 (en) 2001-06-04 2003-12-16 Mark H. Bogart Methods for the treatment of nail fungus and other microbial and mycotic conditions and compositions useful therefor
US6821508B2 (en) 2001-06-27 2004-11-23 Rutgers, The State University Composition and method for topical nail treatment
AU2002331001A1 (en) 2001-08-07 2003-02-24 Dow Corning Corporation Hair and skin care compositions containing siloxane-based polyamide copolymers
US7043791B2 (en) 2001-10-16 2006-05-16 Aubex Corporation Applicator
US6846837B2 (en) 2002-06-21 2005-01-25 Howard I. Maibach Topical administration of basic antifungal compositions to treat fungal infections of the nails
JP2004083439A (ja) 2002-08-23 2004-03-18 Ss Pharmaceut Co Ltd 爪用抗真菌外用剤
DE60318867T2 (de) 2002-09-05 2009-01-15 Galderma S.A. Lösung für die anwendung an nägeln
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US20050142094A1 (en) 2003-03-12 2005-06-30 Manoj Kumar Use of repeat sequence protein polymers in personal care compositions
US20040180025A1 (en) 2003-03-12 2004-09-16 New Life Resources, Llc Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations
AU2004224326B2 (en) 2003-03-21 2010-04-22 Nexmed Holdings, Inc. Antifungal nail coat and method of use
FR2856301B1 (fr) 2003-06-23 2007-08-03 Galderma Res & Dev Composition sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase non polaire non volatile
GB2407496A (en) 2003-10-27 2005-05-04 Dow Corning Method for forming a polysiloxane film on a biological surface
FR2862540B1 (fr) 2003-11-21 2007-03-30 Galderma Res & Dev Composition sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase non polaire non volatile
MXPA06005587A (es) 2003-11-21 2006-08-11 Galderma Res & Dev Composicion rociable para administracion de derivados de vitamina d.
WO2005065668A2 (en) 2003-12-29 2005-07-21 Qlt Usa, Inc. Topical compositions comprising halo-deoxyadenosines for treatment of skin disorders
US7622844B1 (en) 2003-12-30 2009-11-24 Hipercon, Llc Metal fiber brush interface conditioning
US20050176650A1 (en) 2004-02-09 2005-08-11 Xanodyne Pharmacal, Inc. Stable parenteral formulation of levomepromazine and a method for stabilizing said formulation
FR2871697B1 (fr) 2004-06-17 2007-06-29 Galderma Sa Composition sous forme de spray comprenant une association d'actifs pharmaceutiques, une phase alcoolique, au moins un silicone volatile et une phase huileuse non volatile
US20060008538A1 (en) 2004-07-07 2006-01-12 Wu Jeffrey M Methods of treating the skin
US20070082039A1 (en) 2004-10-18 2007-04-12 Jones Gerald S Jr Synthesis of fatty alcohol esters of alpha-hydroxy carboxylic acids, the use of the same as percutaneous permeation enhancers, and topical gels for the transdermal delivery of steroids
US20060110415A1 (en) 2004-11-22 2006-05-25 Bioderm Research Topical Delivery System for Cosmetic and Pharmaceutical Agents
US20060165747A1 (en) 2005-01-24 2006-07-27 David Rolf Antifungal composition, method and kit for topically treating onychomycosis
EP3424932B1 (en) 2005-02-16 2021-04-07 Anacor Pharmaceuticals, Inc Boronophthalides for therapeutic use
US20060280706A1 (en) 2005-05-25 2006-12-14 L'oreal Rinse-off cosmetic composition containing interference particles
US20070071705A1 (en) 2005-09-29 2007-03-29 De Oliveira Monica A M Topical anti-microbial compositions
EP1959929A4 (en) 2005-12-14 2012-08-15 Zars Pharma Inc COMPOSITIONS AND METHODS FOR TREATING DERMATOLOGICAL SUFFERING
US20070142478A1 (en) 2005-12-21 2007-06-21 Erning Xia Combination antimicrobial composition and method of use
KR20080110984A (ko) 2005-12-30 2008-12-22 아나코르 파마슈티칼스 인코포레이티드 보론함유 소분자
CN101460060A (zh) 2006-03-01 2009-06-17 特莱斯特拉塔公司 局部治疗焦油响应性皮肤病用的组合物和方法
US20070207107A1 (en) 2006-03-03 2007-09-06 Gareth Winckle Silicone based emulsions for topical drug delivery
CA2645073A1 (en) 2006-03-08 2007-09-13 Nuviance, Inc. Transdermal drug delivery compositions and topical compositions for application on the skin
US8268876B2 (en) 2006-03-08 2012-09-18 Nihon Nohyaku Co., Ltd. Pharmaceutical composition for external use
US7950865B2 (en) 2006-03-21 2011-05-31 L'oreal Packaging and applicator device
EP2010220B1 (en) 2006-04-03 2022-02-16 Ceva Animal Health Pty Ltd Stabilized pentosan polysulfate (pps) formulations
WO2008001200A2 (en) 2006-06-29 2008-01-03 Antares Pharma Ipl Ag Transdermal composition having enhanced color stability
MXPA06008988A (es) 2006-08-08 2008-02-07 Fernando Ahumada Ayala Preparaciones topicas antiacne que contienen retinoide (tazaroteno o adapaleno), antibiotico (fosfato de clindamicina) y/o queratolitico (peroxido de bonzoilo en microesponjas).
US20080317684A1 (en) 2006-09-06 2008-12-25 Isw Group, Inc. Topical Compositions
PT2116243E (pt) 2006-12-28 2010-10-26 Kaken Pharma Co Ltd Composição de gel para tratamento de micoses
WO2008124131A1 (en) 2007-04-05 2008-10-16 The John Hopkins University Antifungal agents as neuroprotectants
US20090175810A1 (en) * 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
JP2009263346A (ja) 2008-03-31 2009-11-12 Kose Corp カイネチンを含有する乳化型化粧料
AU2009339445A1 (en) * 2009-02-05 2011-08-18 Targeted Delivery Technologies Limited Methods of reducing the proliferation and viability of microbial agents
JP5654497B2 (ja) 2009-02-13 2015-01-14 トピカ ファーマシューティカルズ,インコーポレイテッド 抗真菌製剤
FR2942716B1 (fr) 2009-03-06 2011-04-15 Galderma Res & Dev Methode de solubilisation d'agent antifongique et compositions a haute concentration en agent antifongique applicables sur l'ongle
US20120183531A1 (en) 2009-07-14 2012-07-19 Biogen Idee Ma Inc Methods for Inhibiting Yellow Color Formation in a Composition
WO2011045765A1 (en) * 2009-10-14 2011-04-21 Scuola Internazionale Superiore Di Studi Avanzati TEMPORALLY PATTERNED OVEREXPRESSION OF Foxg1 AND Emx2 TRANSCRIPTION FACTOR GENES IN NEURAL PRECURSORS FOR BRAIN TISSUE REPAIR
WO2011064558A2 (en) * 2009-11-30 2011-06-03 Cipla Limited Pharmaceutical composition
FR2954164B1 (fr) 2009-12-18 2012-03-16 Galderma Pharma Sa Composition antifongique destinee a etre appliquee sur l'ongle perfore
JP2013526565A (ja) * 2010-05-20 2013-06-24 ヒョン チョン,チュン 抗菌及び抗真菌効果に優れた皮膚外用剤組成物
RS62583B1 (sr) 2010-06-29 2021-12-31 Merck Sharp & Dohme Formulacije intravenskog rastvora sa posakonazolom, stabilisane supstituisanim beta-ciklodekstrinom
US8039494B1 (en) 2010-07-08 2011-10-18 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
US8871942B2 (en) * 2010-08-31 2014-10-28 Kaken Pharmaceutical Co., Ltd. Process for producing 1-triazole-2-butanol derivatives
JP6005344B2 (ja) 2011-07-05 2016-10-12 科研製薬株式会社 爪白癬薬用塗布具
HK1211311A1 (en) 2012-02-28 2016-05-20 锡德克斯药物公司 Alkylated cyclodextrin compositions and processes for preparing and using the same
WO2015051183A1 (en) 2013-10-03 2015-04-09 Dow Pharmaceutical Sciences, Inc. Stabilized efinaconazole compositions
CN112999223A (zh) 2013-11-22 2021-06-22 博世健康爱尔兰有限公司 抗感染的方法、组合物和装置

Also Published As

Publication number Publication date
IL244850A0 (en) 2016-05-31
KR20160068812A (ko) 2016-06-15
AU2014329421B2 (en) 2018-08-02
JP2019108388A (ja) 2019-07-04
JP6774518B2 (ja) 2020-10-28
US20210205457A1 (en) 2021-07-08
IL244850B (en) 2020-04-30
EP3052487A1 (en) 2016-08-10
CA2924748A1 (en) 2015-04-09
CN105683184A (zh) 2016-06-15
CA2924748C (en) 2019-09-03
EP3052487A4 (en) 2017-05-03
US10342875B2 (en) 2019-07-09
US20190358329A1 (en) 2019-11-28
MX363386B (es) 2019-03-20
US10864274B2 (en) 2020-12-15
CN110433291B (zh) 2023-04-28
JP6516759B2 (ja) 2019-05-22
PH12016500586B1 (en) 2020-02-21
SG11201602596UA (en) 2016-04-28
CN110433291A (zh) 2019-11-12
PH12016500586A1 (en) 2016-05-23
US20170326240A1 (en) 2017-11-16
MX2016004168A (es) 2016-09-08
AU2014329421A1 (en) 2016-04-07
JP2020169207A (ja) 2020-10-15
CN105683184B (zh) 2019-05-10
KR102320051B1 (ko) 2021-10-29
US20150099785A1 (en) 2015-04-09
EP3052487B1 (en) 2018-09-05
WO2015051183A1 (en) 2015-04-09
US9662394B2 (en) 2017-05-30
JP2016532722A (ja) 2016-10-20
US12076404B2 (en) 2024-09-03

Similar Documents

Publication Publication Date Title
MY179756A (en) Stabilized efinaconazole formulations
IL244206A0 (en) A pharmaceutical preparation containing a pyrimidine compound as an active ingredient
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
EP4230264A3 (en) Prodrugs of fumarates and their use in treating various deseases
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
PH12015500900B1 (en) A stabilized pemetrexed formulation
WO2015081257A3 (en) Aminopyridine derivatives as tam family kinase inhibitors
IL274635A (en) Stable ascorbic acid preparations and methods of using them
MX367326B (es) Composiciones antimicrobianas.
EP3354254A4 (en) SKIN-SHELLING COMPOSITION WITH BETA-MANGOSTINE AS AN ACTIVE SUBSTANCE
PH12015502118A1 (en) Pyridin-4-yl derivatives
GEP201706760B (en) Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same
IL242195B (en) Dicarboxylic acid compounds, preparations containing them and their uses
MY183068A (en) Pharmaceutical formulation comprising antibody
IN2014DN11078A (enExample)
SG10201900598TA (en) Factor viii formulation
EP3068436A4 (en) Topical pharmaceutical, cosmetic and disinfectant compositions comprising phosphatidylcholine
MX345263B (es) Formulación de pexiganan estable.
WO2014166836A8 (en) Growth hormone compound formulation
PH12017502148A1 (en) Pharmaceutical compositions and use thereof
IN2015DN04074A (enExample)
GEP20196957B (en) Crystalline forms of s-acetyl glutathione, their reparations and uses in pharmaceutical and nutraceutical formulations
WO2015044434A3 (de) FLUOR-9-METHYL-ß-CARBOLINE
MX2018007866A (es) Composiciones para el cuidado personal.